Molecular Pathology Laboratory Network

High-Sensitivity Flow Cytometry for PNH

MPLN offers a high-sensitivity flow cytometry assay for early identification and diagnosis of symptomatic Paroxsymal Nocturnal Hemoglobinuria (PNH); critical for effective patient management and assessment of patient response to immunosuppressive treatment.

PNH testing should be considered for patients with unexplained hemoglobinuria, Coombs-negative hemolytic anemia, thrombosis of unusual sites (including hepatic and cerebral vessels), synchronous thrombosis and cytopenias, myelodysplastic syndromes with unilineage dysplasia, and aplastic anemia.

• Allows earlier identification of patients at risk for PNH than standard flow cytometry.
• Increases rare event detection of a clone to 0.01%.
• Allows detection of small PNH populations in patients with bone marrow failure disorders.
• Reduces false negatives, resulting in a higher sensitivity rate. FLAER, in conjunction with lineage specific markers and GPI-anchor proteins, have a higher specificity than GPI-linked proteins CD55/CD59.
• Increases the specificity of RBC clone types II and III.
• Reported results include quantification of granulocytes, monocyte and RBC clone size, and classification of red blood cells into subtypes II and III.

PNH test information and specimen requirements

Test for PNH once

Test for PNH at least annually

· Hemoglobinuria
· Unexplained hemolysis
· Thrombosis unusual sites
· Thrombocytopenia and macrocytosis